SynthesisFrontiers in medicine2025
The novel ciprofol versus propofol during gastroenteroscopy in Chinese patients: a meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastrointestinal endoscopic interventions have become a routine practice in healthcare institutions. Propofol has been the most preferred general anesthetic agent for gastrointestinal endoscopic interventions. Ciprofol is a novel compound that has been approved by the China Medical Products Administration for sedation during gastrointestinal endoscopic procedures since December 2020. In this analysis, we aimed to systematically compare ciprofol versus propofol during gastroenteroscopy in Chinese patients. Methods: The search databases included MEDLINE, EMBASE, Google scholar, Web of Science, http://www.Clinicaltrials.gov, and the Cochrane database. Studies which were based on Chinese participants were included in this analysis. The procedural outcomes and adverse drug events were considered as the endpoints. Statistical analysis was carried out by the RevMan software version 5.4. Risk ratios (RR) with 95% confidence intervals (CI) were used to represent results for dichotomous data whereas weighted mean differences (WMD) with 95% CI were used to represent the result for continuous data. Results: Twelve studies with a total number of 2055 Chinese participants (enrolled from 2017 to 2023) were included in this analysis whereby 1073 participants were assigned to ciprofol and 982 participants were assigned to propofol. Following the administration of anesthetic agent, the results for the induction time [WMD: 0.33; (95% CI: -0.64 to 1.30); Conclusion: Through this meta-analysis, it could be concluded that ciprofol was apparently not associated with significantly worse procedural outcomes nor associated with increased adverse drug events compared to propofol during gastroenteroscopy in Chinese patients. However, in view of several limitations in this analysis, this hypothesis should further be confirmed in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.